ARTL ARTELO BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1621221 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.4%
TTM EPS YoY188.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-404.2%
ROA-206.9%
ROIC (approx.)-398.3%
Asset turnover—
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-83.52x
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $803,000 | $876,000 | $773,000 | $893,000 | $1.27M | $1.87M | $1.38M | $2.48M |
| SG&A expense | $989,000 | $1.63M | $1.92M | $1.89M | $1.81M | $1.28M | $995,000 | $1.34M |
| Operating income | -$1.79M | -$2.50M | -$2.69M | -$2.79M | -$3.09M | -$3.15M | -$2.38M | -$3.81M |
| Interest expense | $0 | $6,000 | $100,000 | $11,000 | $111,000 | $72,000 | $0 | $0 |
| Income tax | — | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.77M | -$2.43M | -$2.96M | -$4.17M | -$3.12M | -$3.22M | -$2.37M | -$3.78M |
| EPS (diluted) | -3.19 | -0.89 | -4.00 | — | -88.80 | -16.86 | -12.55 | — |
| Weighted avg. shares (diluted) | 554,197 | 2.71M | 739,000 | — | 35,136 | 191,000 | 189,000 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4,198 | $4.44M | $4.20M | $600,000 | $1.72M | $2.07M | $746,000 | $2.34M |
| Short-term investments | — | — | — | — | $0 | $0 | $0 | $0 |
| Current assets | $4.60M | $4.37M | $10.42M | $695,000 | $1.83M | $2.23M | $1.38M | $2.56M |
| Intangibles | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M |
| Total assets | $6.67M | $6.46M | $12.52M | $2.80M | $4.27M | $4.36M | $3.52M | $4.70M |
| Current liabilities | $439,000 | $1.46M | $5.83M | $4.04M | $4.86M | $5.71M | $2.80M | $1.77M |
| Total liabilities | $439,000 | $1.46M | $5.85M | $4.07M | $4.90M | $5.76M | $2.86M | $1.84M |
| Shareholders' equity | $6.24M | $5.00M | $6.67M | -$1.27M | -$635,000 | -$1.41M | $651,000 | $2.86M |
| Shares outstanding | 937,177 | 673,008 | 673,008 | 74,779 | 1.56M | 704,425 | 3.28M | 567,582 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.62M | -$5.03M | -$1.19M | -$2.91M | -$3.50M | -$514,000 | -$1.60M | -$2.57M |
| Investing cash flow | — | — | — | $188,000 | -$250,000 | $0 | $0 | $500,000 |
| Financing cash flow | $2.86M | -$1.06M | $10.86M | $1.61M | $3.44M | $1.82M | $0 | $57,000 |
| Stock-based compensation | -$354,000 | $570,000 | $401,000 | $368,000 | $432,000 | $150,000 | $192,000 | $201,000 |
Free plan shows the latest 8 periods; Pro shows all 56 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.